This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ment, L. R.
Right arrow Articles by Makuch, R. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ment, L. R.
Right arrow Articles by Makuch, R. W.
Related Collections
Right arrow Premature & Newborn

PEDIATRICS Vol. 105 No. 3 March 2000, pp. 485-491

Outcome of Children in the Indomethacin Intraventricular Hemorrhage Prevention Trial

Received Apr 8, 1999; accepted Aug 9, 1999.

Laura R. Ment*, Dagger , Betty Vohr§, Walter Allanparallel , Michael Westerveld, Sara S. Sparrow#, Karen C. Schneider*, Karol H. Katz**, Charles C. DuncanDagger Dagger , and Robert W. Makuch**

From the Departments of * Pediatrics, Dagger  Neurology,  Neurosurgery, # Child Study Center, ** Epidemiology and Public Health, and Dagger Dagger  Neurosurgery, Yale University School of Medicine, New Haven, Connecticut; the § Department of Pediatrics, Brown University School of Medicine, Providence, Rhode Island; and the parallel  Departments of Pediatrics and Neurology, Maine Medical Center, Portland, Maine.

Background.  For preterm infants, intraventricular hemorrhage (IVH) may be associated with adverse neurodevelopmental outcome. We have demonstrated that early low-dose indomethacin treatment is associated with a decrease in both the incidence and severity of IVH in very low birth weight preterm infants. In addition, we hypothesized that the early administration of low-dose indomethacin would not be associated with an increase in the incidence of neurodevelopmental handicap at 4.5 years of age in our study children.

Methods.  To test this hypothesis, we provided neurodevelopmental follow-up for the 384 very low birth weight survivors of the Multicenter Randomized Indomethacin IVH Prevention Trial. Three hundred thirty-seven children (88%) were evaluated at 54 months' corrected age, and underwent neurodevelopmental examinations, including the Wechsler Preschool and Primary Scale of Intelligence-Revised (WPPSI-R), the Peabody Picture Vocabulary Test-Revised (PPVT-R), and standard neurologic examinations.

Results.  Of the 337 study children, 170 had been randomized to early low-dose indomethacin therapy and 167 children had received placebo. Twelve (7%) of the 165 indomethacin children and 11 (7%) of the 158 placebo children who underwent neurologic examinations were found to have cerebral palsy. For the 233 English-monolingual children for whom cognitive outcome data follow, the mean gestational age was significantly younger for the children who received indomethacin than for those who received placebo. In addition, although there were no differences in the WPPSI-R or the PPVT-R scores between the 2 groups, analysis of the WPPSI-R full-scale IQ by function range demonstrated significantly less mental retardation among those children randomized to early low-dose indomethacin (for the indomethacin study children, 9% had an IQ <70, 12% had an IQ of 70-80, and 79% had an IQ >80, compared with the placebo group, for whom 17% had an IQ <70, 18% had an IQ of 70-80, and 65% had an IQ >80). Indomethacin children also experienced significantly less difficulty with vocabulary skills as assessed by the PPVT-R when compared with placebo children.

Conclusions.  These data suggest that, for preterm neonates, the early administration of low-dose indomethacin therapy is not associated with adverse neurodevelopmental function at 54 months' corrected age.  Key words:  low-dose indomethacin, preterm infant, neurodevelopmental outcome, intraventricular hemorrhage.




This article has been cited by other articles:


Home page
 PediatricsHome page
I. Adams-Chapman, N. I. Hansen, B. J. Stoll, R. Higgins, and for the NICHD Research Network
Neurodevelopmental Outcome of Extremely Low Birth Weight Infants With Posthemorrhagic Hydrocephalus Requiring Shunt Insertion
Pediatrics, May 1, 2008; 121(5): e1167 - e1177.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child. Fetal Neonatal Ed.Home page
P. J McNamara and A. Sehgal
Towards rational management of the patent ductus arteriosus: the need for disease staging
Arch. Dis. Child. Fetal Neonatal Ed., November 1, 2007; 92(6): F424 - F427.
[Full Text] [PDF]

Home page
 PediatricsHome page
M. E. Msall
The Limits of Viability and the Uncertainty of Neuroprotection: Challenges in Optimizing Outcomes in Extreme Prematurity
Pediatrics, January 1, 2007; 119(1): 158 - 160.
[Full Text] [PDF]

Home page
 NeoReviewsHome page
L. Romantseva and M. E Msall
Advances in Understanding Cerebral Palsy Syndromes After Prematurity
NeoReviews, November 1, 2006; 7(11): e575 - e585.
[Full Text] [PDF]

Home page
 PediatricsHome page
S. P. Miller, E. E. Mayer, R. I. Clyman, D. V. Glidden, S. E.G. Hamrick, and A. J. Barkovich
Prolonged Indomethacin Exposure Is Associated With Decreased White Matter Injury Detected With Magnetic Resonance Imaging in Premature Newborns at 24 to 28 Weeks' Gestation at Birth
Pediatrics, May 1, 2006; 117(5): 1626 - 1631.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
R. D. Higgins, M. Delivoria-Papadopoulos, and T. N.K. Raju
Executive Summary of the Workshop on the Border of Viability
Pediatrics, May 1, 2005; 115(5): 1392 - 1396.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
D. W. Brown, D. Lee, V. S. Kumaran, and T.-Y. Lee
Age-dependent cerebral hemodynamic effects of indomethacin in the newborn piglet
J Appl Physiol, November 1, 2004; 97(5): 1880 - 1887.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
B. R. Vohr, W. C. Allan, M. Westerveld, K. C. Schneider, K. H. Katz, R. W. Makuch, and L. R. Ment
School-Age Outcomes of Very Low Birth Weight Infants in the Indomethacin Intraventricular Hemorrhage Prevention Trial
Pediatrics, April 1, 2003; 111(4): e340 - 346.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
L. R. Ment, B. Vohr, W. Allan, K. H. Katz, K. C. Schneider, M. Westerveld, C. C. Duncan, and R. W. Makuch
Change in Cognitive Function Over Time in Very Low-Birth-Weight Infants
JAMA, February 12, 2003; 289(6): 705 - 711.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
S. Saigal, B. L. Stoskopf, D. L. Streiner, and E. Burrows
Physical Growth and Current Health Status of Infants Who Were of Extremely Low Birth Weight and Controls at Adolescence
Pediatrics, August 1, 2001; 108(2): 407 - 415.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
B. Schmidt, P. Davis, D. Moddemann, A. Ohlsson, R. S. Roberts, S. Saigal, A. Solimano, M. Vincer, L. L. Wright, and the Trial of Indomethacin Prophylaxis in Preterms
Long-Term Effects of Indomethacin Prophylaxis in Extremely-Low-Birth-Weight Infants
N. Engl. J. Med., June 28, 2001; 344(26): 1966 - 1972.
[Abstract] [Full Text] [PDF]